Clinical trial
A Dose Finding Study of ZW49 in Patients With HER2-Positive Cancers
NCT03821233
Study timeline
Study start (actual)2019-04-15Date precision: day
Registry last updated2025-01-29
Observed by CureCurrent2026-10-07
Recorded dates are source observations, not predictions. Missing milestones are not estimated.
Conditions
HER2-expressing Cancersunresolved
Interventions
ZW49DRUG
Sponsors & collaborators
Zymeworks BC Inc.lead sponsor
Mapped research locations
SeoulSouth Korea4New YorkNew York, United States1ChicagoIllinois, United States1PhiladelphiaPennsylvania, United States1TorontoOntario, Canada1San AntonioTexas, United States1NashvilleTennessee, United States1TampaFlorida, United States1MontrealQuebec, Canada1FairfaxVirginia, United States1DuarteCalifornia, United States1
Registry source
Open the source record to verify current eligibility, contacts, locations and registry updates.
Open NCT03821233 on ClinicalTrials.gov ↗Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.